RNS Number : 4867P
Avacta Group PLC
02 July 2025
 

 

Avacta Group plc

 

("Avacta" or the "Group" or the "Company")

Result of AGM

LONDON and PHILADELPHIA - July, 2 2025 - Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces that at the Annual General Meeting (AGM) held this morning, all resolutions were duly passed by shareholders (with the exception of Resolution 3 which was not put to the meeting).

The results of the voting at the AGM are outlined in the table below and the presentation materials are available on the Company's website here.

 

For

Against

Withheld

Resolution

Votes

%

Votes

%

Votes

1

69,286,714

99.84%

111,935  

0.16%

2,231,336

2

52,723,506

77.25%

15,527,142

22.75%

3,379,337

3

See above

-

See above

-

See above

4

70,378,158

99.32%

482,896

0.68%

768,931

5

68,687,888

98.79%

843,416

1.21%

2,098,681

6

68,241,916

97.50%

1,747,126

2.50%

1,640,943

7

70,242,593

99.58%

293,323

0.42%

1,094,069

8

61,988,039

90.99%

6,139,673

9.01%

3,502,273

9

64,805,029

98.71%

850,095

1.29%

5,974,861

10

65,957,356

97.83%

1,462,237

2.17%

4,210,392

11

64,414,344

96.66%

2,229,203

3.34%

4,986,438

12

64,418,047

96.71%

2,189,948

3.29%

5,021,990

13

67,217,793

99.14%

580,188

0.86%

3,832,004

Although all the resolutions were passed, the Board of Avacta notes that more than 20% of votes were cast against Resolution 2. The Board will continue to engage with shareholders in the periods ahead and remains committed to open and constructive dialogue in order to understand shareholders' views. To this end, shareholders who voted against resolution 2 can email any views to avacta@icrhealthcare.com.  

 

-Ends -

 

For further information from Avacta Group plc, please contact:

 

Avacta Group plc

Michael Vinegrad,

Group Communications Director

 

https://avacta.com/

 

Peel Hunt (Nomad and Joint Broker)

James Steel / Chris Golden

 

 www.peelhunt.com

 

Panmure Liberum (Joint Broker)

Emma Earl / Will Goode / Mark Rogers

 

Zeus (Joint Broker)

James Hornigold / George Duxberry

Dominic King

 

ICR Healthcare

Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert

 

 www.panmureliberum.com

 

 

www.zeuscapital.co.uk

 

 

 

avacta@icrhealthcare.com

 

 

Investor Contact

Renee Leck

THRUST Strategic Communications

 

renee@thrustsc.com

 

Media Contact

Carly Scaduto

Carly Scaduto Consulting

Carly@carlyscadutoconsulting.com 

 

 

About Avacta - https://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGEASXAESASEFA